NDRA (endrainc.com) יחס שווי שוק לשווי בספרים

The early sales stage of liver diagnostic systems is constraining margin growth, as reflected in the price-to-book value trend on GURU.Markets, where the 1.19 mark indicates the current state for ENDRA Life Sciences (NDRA). The situation is further complicated by fabless-model risks stemming from contractor dependency and geopolitical barriers that hinder global testing and the export of equipment to unstable regions.

For ENDRA Life Sciences (NDRA), the "value trap" risk is intensified by an FDA regulatory deadlock blocking expansion in the US. This metric is calculated as the ratio of market price to book value, measuring the premium or discount of asset value. The current ratio of the company's market capitalization to its book capitalization stands at 1.19. The price action on this chart allows for an assessment of the business's degree of undervaluation against the backdrop of European pilots. This determines the real cost of capital amid stagnant base growth.